See analyst estimates and all valuation multiples for Pharmacies
Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
$150B | 0.4x | 9.8x | |
$38.7B | 0.3x | 10.3x | |
$26.1B | 8.0x | 32.4x | |
$9.3B | 1.1x | 22.3x | |
$8.2B | 1.9x | 36.0x | |
$7.5B | 0.2x | 3.5x | |
$7.4B | 1.0x | 10.3x | |
$6.8B | 0.6x | 11.7x | |
$5.7B | 0.8x | 9.6x | |
$5.2B | 2.0x | 15.1x | |
$4.8B | 0.7x | 11.2x | |
$4.4B | 1.7x | 10.1x | |
$4.0B | 0.4x | 9.4x | |
$3.9B | 1.1x | 9.8x | |
$3.9B | 0.6x | 9.1x | |
$3.7B | 0.2x | 5.7x | |
$3.6B | 0.6x | 8.7x | |
$3.4B | 0.6x | 7.9x | |
$2.8B | 0.7x | 6.2x | |
$2.7B | 0.9x | 52.8x | |
$2.7B | 0.8x | 10.5x | |
$2.7B | 0.4x | 5.4x | |
$2.4B | 0.8x | 7.3x | |
$2.3B | 1.3x | 9.2x | |
$1.9B | 0.9x | 10.6x | |
$1.6B | 2.0x | 6.1x | |
$1.4B | 2.0x | 24.3x | |
$1.4B | 1.3x | 11.0x | |
$1.4B | 0.4x | 6.2x | |
$1.3B | 0.5x | 10.7x | |
$1.2B | n/a | n/a | |
$1.1B | n/a | n/a | |
$1.0B | n/a | n/a | |
$1.0B | n/a | n/a | |
$964M | 0.4x | 6.6x | |
$908M | 0.7x | n/a | |
$839M | 1.4x | 15.5x | |
$748M | 0.6x | -15.3x | |
$688M | n/a | n/a | |
$665M | n/a | n/a | |
$646M | n/a | n/a | |
$607M | 0.2x | 26.0x | |
$278M | 0.1x | n/a | |
$264M | n/a | n/a | |
$203M | 0.5x | 8.5x | |
$147M | 0.1x | 4.3x | |
$144M | n/a | n/a | |
$105M | n/a | n/a | |
$83.9M | 0.6x | 15.4x | |
$48.5M | n/a | n/a | |
$27.9M | 0.4x | 44.2x | |
$26.4M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Pharmacies